KR102482826B1 - 아비박탐 유리 산 - Google Patents

아비박탐 유리 산 Download PDF

Info

Publication number
KR102482826B1
KR102482826B1 KR1020197008169A KR20197008169A KR102482826B1 KR 102482826 B1 KR102482826 B1 KR 102482826B1 KR 1020197008169 A KR1020197008169 A KR 1020197008169A KR 20197008169 A KR20197008169 A KR 20197008169A KR 102482826 B1 KR102482826 B1 KR 102482826B1
Authority
KR
South Korea
Prior art keywords
avibactam
formula
acid
crystalline form
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197008169A
Other languages
English (en)
Korean (ko)
Other versions
KR20190040988A (ko
Inventor
미하엘 피셔
안드레아스 레히너
브리기테 슈타글
Original Assignee
산도즈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산도즈 아게 filed Critical 산도즈 아게
Publication of KR20190040988A publication Critical patent/KR20190040988A/ko
Application granted granted Critical
Publication of KR102482826B1 publication Critical patent/KR102482826B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020197008169A 2016-08-26 2017-08-25 아비박탐 유리 산 Active KR102482826B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16185913.7 2016-08-26
EP16185913 2016-08-26
PCT/EP2017/071471 WO2018037124A1 (en) 2016-08-26 2017-08-25 Avibactam free acid

Publications (2)

Publication Number Publication Date
KR20190040988A KR20190040988A (ko) 2019-04-19
KR102482826B1 true KR102482826B1 (ko) 2022-12-28

Family

ID=56802364

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008169A Active KR102482826B1 (ko) 2016-08-26 2017-08-25 아비박탐 유리 산

Country Status (8)

Country Link
US (1) US11124513B2 (https=)
EP (1) EP3504207B1 (https=)
JP (1) JP7183147B2 (https=)
KR (1) KR102482826B1 (https=)
CN (1) CN109641901B (https=)
AU (1) AU2017315164B2 (https=)
CA (1) CA3034470A1 (https=)
WO (1) WO2018037124A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3580221B1 (en) 2017-02-08 2020-12-16 Sandoz AG Process for the preparation of crystalline form c of avibactam sodium
CN113105455B (zh) * 2020-01-10 2024-05-17 四川科伦药物研究院有限公司 晶型b阿维巴坦钠的制备方法
CN115677697B (zh) * 2022-09-19 2024-08-06 瑞阳制药股份有限公司 粒度可调控且流动性好的b晶型阿维巴坦钠析晶方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010172A1 (fr) * 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
WO2011042560A1 (en) * 2009-10-09 2011-04-14 Novexel Sa Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9567335B2 (en) 2013-03-08 2017-02-14 Wockhardt Limited Process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
WO2016046845A1 (en) * 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
US10265326B2 (en) 2015-08-10 2019-04-23 Sandoz Ag Form C of avibactam sodium
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010172A1 (fr) * 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
WO2011042560A1 (en) * 2009-10-09 2011-04-14 Novexel Sa Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
[(2S,5R)-2carbamolyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate, CAS Registry No. 1192500-31-4(2009.11.16.)*
https://www.avycaz.com의 wayback machine (2015.06.30., 검색일 2022.01.30.)*

Also Published As

Publication number Publication date
AU2017315164A1 (en) 2019-02-28
US20190185473A1 (en) 2019-06-20
KR20190040988A (ko) 2019-04-19
CN109641901B (zh) 2022-12-09
EP3504207B1 (en) 2022-06-01
EP3504207A1 (en) 2019-07-03
AU2017315164B2 (en) 2021-12-09
US11124513B2 (en) 2021-09-21
JP2019524829A (ja) 2019-09-05
CN109641901A (zh) 2019-04-16
CA3034470A1 (en) 2018-03-01
WO2018037124A1 (en) 2018-03-01
JP7183147B2 (ja) 2022-12-05

Similar Documents

Publication Publication Date Title
JP6028016B2 (ja) リナグリプチンベンゾエートの多形体
JP7075884B2 (ja) アビバクタムナトリウムのｃ形
KR102482826B1 (ko) 아비박탐 유리 산
CA2716914A1 (en) Novel crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
JP2026032038A (ja) 結晶
JP2005298424A (ja) エパルレスタット結晶の製造方法
US10919893B2 (en) Process for the preparation of crystalline form C of avibactam sodium
CN116997331A (zh) 固体形式的喹诺酮化合物及其制备方法
JP2012513440A (ja) 有機化合物の結晶形態
JP7045795B2 (ja) 結晶性β－ラクタマーゼ阻害剤
JP2017530106A (ja) ３−［（ジメチルアミノ）メチル］ｎ−｛２−［４−（ヒドロキシカルバモイル）フェノキシ］エチル｝−１−ベンゾフラン−２−カルボキサミドの新規の塩、関連する結晶形態、それを調製するための方法、並びにそれを含有している医薬組成物
US20250026777A1 (en) Cocrystals of nicotinamide riboside salts, crystalline forms, methods of preparation, and applications thereof
RU2827357C1 (ru) Новые формы (1r,2s,5s)-n-[(1s)-1-циано-2-[(3s)-2-оксопирролидин-3-ил]этил]-3-[(2s)-3,3-диметил-2-[(2,2,2-трифторацетил)амино]бутаноил]-6,6-диметил-3-азабицикло[3.1.0]гексан-2-карбоксамида
EP4592292A1 (en) Stable monohydrate form of avibactam sodium salt and preparation method therefor
EP3181565A1 (en) Crystalline omarigliptin salts
CN109879863A (zh) 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法
CA2797350A1 (en) Co-crystal intermediates of rosuvastatin and methods of using same
EP2980091A1 (en) Novel hydrates of dolutegravir sodium
US20110237680A1 (en) Crystal forms of o-desmethylvenlafaxine fumarate

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4